CTKB Stock Analysis: Buy, Sell, or Hold?
CTKB - Cytek Biosciences, Inc. Common Stock
$3.86
0.09 (2.39%)
▲
5d:
-2.53%
30d:
+2.39%
90d:
-13.84%
HOLD
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When CTKB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CTKB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CTKB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: CTKB is currently trading at $3.86, which is considered fair relative to its 30-day fair value range of $3.71 to $4.19. From a valuation perspective, the stock is trading at a discount (Forward PE: 20.3) compared to its historical average (66.8). Remarkably, the market is currently pricing in an annual earnings decline of 32.7% over the next few years. This pessimistic expectation contrasts with the company's recent 73.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, CTKB is in a downtrend. Immediate support is located at $3.70, while resistance sits at $4.20.
Market Sentiment: CTKB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.69 (+47.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CTKB is in a downtrend. Immediate support is located at $3.70, while resistance sits at $4.20.
Market Sentiment: CTKB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.69 (+47.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.71 -
$4.19
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 47.3% below Wall St target ($5.69)
Trading Range Analysis
30-Day Trading Range
$3.71 -
$4.19
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.70
Resistance Level
$4.20
Current Trend
Downtrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.32
Wall Street Target
$5.69
(+47.3%)
Revenue Growth (YoY)
6.5%
Earnings Growth (YoY)
73.5%
Profit Margin
-36.2%
Valuation Discount vs History
-32.7% cheaper
PE vs Historical
20.3 vs 66.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-32.7%
(market-implied from PE analysis)
1-Year Target
$3.47
(-10%)
2-Year Target
$3.13
(-19%)
3-Year Target
$2.81
(-27%)
3-Yr Target (if PE normalizes)
(PE: 20→67)
$9.25
(+140%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 20.3 to 66.8
Stabilization Target:
$12.69
(+228.8%)
PE Expansion Potential:
+228.8%
Share & Embed Analysis
Last updated: June 23, 2026 7:59 AM ET
Data refreshes hourly during market hours. Next update: 8:59 AM
Data refreshes hourly during market hours. Next update: 8:59 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTKB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$77 | 52 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 57 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 61 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$242 | 60 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 63 BUY |
